Physician profile
Conrad H Knudson
NPI 1699773481
$1,045.09
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $163 · 2021: $434 · 2022: $199.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.84 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $94.79 | 2021 | |
| Pfizer INC. | $87.97 | 2019-2022 | |
| Allergan, INC. | $78.40 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $77.54 | 2019-2022 | |
| Novo Nordisk INC | $71.44 | 2019-2020 | |
| Lilly USA, LLC | $37.25 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.84 | 2019-2022 | |
| Amgen INC. | $30.40 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.29 | 2019 | |
| Genentech USA, INC. | $21.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.42 | 2019 | |
| Dexcom, INC. | $16.30 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.81 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.79 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2021 | |
| Nabriva Therapeutics, Plc | $11.52 | 2021 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conrad Knudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.